“It is very encouraging that this abstract has been accepted for an international health economic scientific conference of this magnitude”, said Bengt Gustavsson, Director of Clinical Development and Medical Affairs of Nanexa. “A Systematic Literature Review is always one of the cornerstones on which you build your health economical strategy. This strategy in turn leads to the price model used in future price negotiations with payers in different countries. We see from our data that adherence to drug treatments for multiple myeloma is not always as good as expected, that more research is needed in this particular area and that there is a need for a long-acting product like NEX-20 that can improve adherence to treatment.”